Literature DB >> 1985208

Induction of high-titer neutralizing antibodies, using hybrid human immunodeficiency virus V3-Ty viruslike particles in a clinically relevant adjuvant.

J C Griffiths1, E L Berrie, L N Holdsworth, J P Moore, S J Harris, J M Senior, S M Kingsman, A J Kingsman, S E Adams.   

Abstract

The localization of neutralization determinants within the envelope glycoproteins of human immunodeficiency virus (HIV) has been largely achieved by immunizing small animals in conjunction with Freund's adjuvant. However, for eventual use in humans, candidate HIV vaccine components must also be efficacious in a nontoxic formulation. We describe here the production of hybrid Ty viruslike particles carrying the major neutralizing domain of HIV and demonstrate the induction of high-titer virus-neutralizing antibodies and an HIV-specific T-cell proliferative response after immunization in conjunction with aluminum hydroxide. As aluminum hydroxide and aluminum phosphate are the only adjuvants currently licensed for use in humans, these observations have implications for the development of an effective vaccine against HIV.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1985208      PMCID： PMC240536     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  42 in total

1.  HIV p24-specific helper T cell clones from immunized primates recognize highly conserved regions of HIV-1.

Authors:  K H Mills; P A Kitchin; B P Mahon; A L Barnard; S E Adams; S M Kingsman; A J Kingsman
Journal:  J Immunol       Date:  1990-03-01       Impact factor: 5.422

2.  Envelope sequences of two new United States HIV-1 isolates.

Authors:  C Gurgo; H G Guo; G Franchini; A Aldovini; E Collalti; K Farrell; F Wong-Staal; R C Gallo; M S Reitz
Journal:  Virology       Date:  1988-06       Impact factor: 3.616

3.  Inhibition of CD4+ T cell function by the HIV envelope protein, gp120.

Authors:  D C Diamond; B P Sleckman; T Gregory; L A Lasky; J L Greenstein; S J Burakoff
Journal:  J Immunol       Date:  1988-12-01       Impact factor: 5.422

4.  Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes.

Authors:  T J Palker; T J Matthews; A Langlois; M E Tanner; M E Martin; R M Scearce; J E Kim; J A Berzofsky; D P Bolognesi; B F Haynes
Journal:  J Immunol       Date:  1989-05-15       Impact factor: 5.422

5.  Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4.

Authors:  M A Skinner; A J Langlois; C B McDanal; J S McDougal; D P Bolognesi; T J Matthews
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

6.  An enzyme-linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1.

Authors:  J P Moore; L A Wallace; E A Follett; J A McKeating
Journal:  AIDS       Date:  1989-03       Impact factor: 4.177

7.  Inhibitory influences of envelope glycoproteins of HIV-1 on normal immune responses.

Authors:  N Chirmule; V Kalyanaraman; N Oyaizu; S Pahwa
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1988

8.  Effects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1.

Authors:  P S Linsley; J A Ledbetter; E Kinney-Thomas; S L Hu
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

9.  Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans.

Authors:  J A Berzofsky; A Bensussan; K B Cease; J F Bourge; R Cheynier; Z Lurhuma; J J Salaün; R C Gallo; G M Shearer; D Zagury
Journal:  Nature       Date:  1988-08-25       Impact factor: 49.962

10.  Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120.

Authors:  P W Berman; J E Groopman; T Gregory; P R Clapham; R A Weiss; R Ferriani; L Riddle; C Shimasaki; C Lucas; L A Lasky
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205
View more
  13 in total

1.  Virus-like particles as vaccine adjuvants.

Authors:  S C Gilbert
Journal:  Mol Biotechnol       Date:  2001-10       Impact factor: 2.695

2.  New nucleotide sequence data on the EMBL File Server.

Authors: 
Journal:  Nucleic Acids Res       Date:  1991-06-11       Impact factor: 16.971

3.  Induction of single and dual cytotoxic T-lymphocyte responses to viral proteins in mice using recombinant hybrid Ty-virus-like particles.

Authors:  G T Layton; S J Harris; J Myhan; D West; F Gotch; M Hill-Perkins; J S Cole; N Meyers; S Woodrow; T J French; S E Adams; A J Kingsman
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

4.  Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion.

Authors:  J C Griffiths; S J Harris; G T Layton; E L Berrie; T J French; N R Burns; S E Adams; A J Kingsman
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

5.  Enhanced activation of human T cell clones specific for virus-like particles expressing the HIV V3 loop in the presence of HIV V3 loop-specific polyclonal antibodies.

Authors:  S Peifang; G L Pira; D Fenoglio; S Harris; M G Costa; V Venturino; V Dessì; G Layton; J Laman; J G Huisman
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

6.  Human immunodeficiency virus type 1 major neutralizing determinant exposed on hepatitis B surface antigen particles is highly immunogenic in primates.

Authors:  K Schlienger; M Mancini; Y Rivière; D Dormont; P Tiollais; M L Michel
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

Review 7.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

8.  Poliovirus chimeras expressing sequences from the principal neutralization domain of human immunodeficiency virus type 1.

Authors:  J F Dedieu; J Ronco; S van der Werf; J M Hogle; Y Henin; M Girard
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

9.  Incorporation of pseudorabies virus gD into human immunodeficiency virus type 1 Gag particles produced in baculovirus-infected cells.

Authors:  L Garnier; M Ravallec; P Blanchard; H Chaabihi; J P Bossy; G Devauchelle; A Jestin; M Cerutti
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

10.  Localization of an immunodominant domain on baculovirus-produced parvovirus B19 capsids: correlation to a major surface region on the native virus particle.

Authors:  C S Brown; T Jensen; R H Meloen; W Puijk; K Sugamura; H Sato; W J Spaan
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.